You are looking at 1 - 3 of 3 items for

  • Refine by Access: all x
  • By Author: Wilson, Charles B. x
  • By Author: Fewer, Derek x
Clear All
Restricted access

Justin Renaudin, Derek Fewer, Charles B. Wilson, Edwin B. Boldrey, John Calogero, and K. Jean Enot

✓ Twenty patients seriously ill following subtotal excision of brain tumors were given unusually large doses of Decadron to restrain peritumoral edema. The prompt clinical effect was strikingly favorable in 11. The dosage of Decadron above which no additional anti-edema effect occurs must be established for each individual patient. No significant complications occurred under dosages ranging from 32 to 96 mg/day. Brain scintiscans performed after rapid clinical improvement in five cases showed no change.

Restricted access

Takao Hoshino, Marvin Barker, Charles B. Wilson, Edwin B. Boldrey, and Derek Fewer

✓ Eleven selected patients with brain tumor were given 3H-thymidine intravenously at the time of operation. Parts of the excised tumor were fixed for routine histological studies as well as for simple radioautography. Other parts were minced immediately after excision and incubated at 37°C with 14C-thymidine, and were thus doubly labeled. Simple radioautography of the tumor specimen showed fairly even distribution of labeled cells in the astrocytoma group and uneven labeling of tumor cells in malignant gliomas, including glioblastomas. In most glioblastomas, the labeling index (percentage of cells labeled with 3H-thymidine) varied from near 0% in the necrotic areas to approximately 20% in the most viable parts of the same tumor; the labeling index of viable parts of the tumor ranged from 5% to 10% with the exception of astrocytomas in which the index was 1% or less. The duration of DNA synthesis ranged from 7 to 10 hours in the majority of tumors regardless of the nature or grade of malignancy.

Restricted access

Andrew H. Koo, Derek Fewer, Charles B. Wilson, and Thomas H. Newton

✓ Bis-chlorethyl-nitrosourea (BCNU) is one of the numerous experimental chemotherapeutic agents used to treat recurrent brain tumors. The clinical response and the angiographic changes in tumor vascularity were compared in 32 patients treated with BCNU for recurrent primary brain tumor. In five of 22 initially vascular lesions the tumor vasculature increased, in 11 it decreased, and in six it remained unchanged after treatment. There was no correlation between angiographic changes in the tumor and the clinical course following BCNU therapy.